FindTrial
Sign In

GRANOCYTE 34 Millions UI/ml

DRUG2 trials

Sponsors

Institut Gustave Roussy, Fondazione Telethon Ets, San Raffaele Hospital

Conditions

Non-seminomatous germ-cell tumors (including testisretroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.transfusion-dependent beta-thalassemia

Phase 2

A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
RecruitingCTIS2023-505040-19-00
Institut Gustave RoussyNon-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.
Start: 2023-04-11Target: 150Updated: 2025-03-14
A single arm, open label, multicenter, single-dose, phase 2b clinical study evaluating efficacy and safety of gene therapy using autologous CD34+ hematopoietic stem cells transduced with the GLOBE lentiviral vector using an improved transduction protocol in subjects with transfusion-dependent beta-thalassemia.
Not yet recruitingCTIS2025-522160-32-00
Fondazione Telethon Ets, San Raffaele Hospitaltransfusion-dependent beta-thalassemia
Target: 9Updated: 2025-12-18